Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2)
Journal article published in 2015 by
Edward J. Gane,
Stephen Pianko,
Stuart K. Roberts,
Alex J. Thompson,
Stefan Zeuzem,
E.-L.-I. Zuckerman,
Ziv Ben Ari,
Graham R. Foster,
Kosh Agarwal 
,
Alex L. Laursen,
Jan Gerstoft,
Wei Gao,
Hsueh-Cheng Huang,
Brian Fitzgerald,
Jerry J. Li
and other authors.
,
Alex L. Laursen,
Jan Gerstoft,
Wei Gao,
Hsueh-Cheng Huang,
Brian Fitzgerald,
Jerry J. Li
and other authors.
